Spotlight On... Exit stage left for senior leaders at Intrexon; FDA approves new anthrax therapy; Aveo gets $134M deal for AV-203; Newly merged Vyriad focuses on oncolytics; and more...

Intrexon ($XON) has announced the departure of its chief operating officer, Krish Krishnan, and SVP of product development Suma Krishnan, effective immediately. The Virginia-based firm, which focuses on synthetic biology, said in a statement this was because of the "successful growth of the company"--and also because it has also hired new senior members to run the five business sectors across the company. The two roles will now be spread among a number of existing officers, with Joel Liffmann, SVP of finance, taking on primary responsibility for operating divisions. Randal Kirk, chairman and CEO of Intrexon, said: "I would like to thank Krish and Suma for their contributions to the company." Release

@FierceBiotech: Atlantic Healthcare closes $24M round and gains Salix founder as new CSA. News | Follow @FierceBiotech

@JohnCFierce: Biotech startup trendsetters at Arch hunting up $400M-plus for venture fund. Report | Follow @JohnCFierce

> The FDA approved Elusys' anthrax treatment Anthim (obiltoxaximab), which is used with antibacterials. The biotech developed the drug with help from BARDA, which is backing a range of new bioterrorism-related therapies. Release

> Aveo Oncology snagged a $1 million upfront from Beijing-based CANbridge life sciences for an Asian licensing pact for AV-203, AVEO's clinical-stage ErbB3 (HER3) antibody candidate. Aveo is also in line for up to $133 million in milestones. Release

> Omnis Pharma and Magnis Therapeutics are merging into Vyriad, a clinical-stage oncolytic immunovirotherapy development company. Release

Medical Device News

@FierceMedDev: ICYMI Friday: J&J highlights consumer devices, most investable 6 device segments in quest for growth. Article | Follow @FierceMedDev

@EmilyWFierce: ICYMI from FiercePharma: Senators lambaste Turing for 'unethical' price hikes at latest drug price hearing. Report | Follow @EmilyWFierce

> Med tech consultant discusses China FDA, tries to clear up Chinese clinical trial confusion. Editor's corner

> J&J moves to settle swath of lawsuits over power morcellator devices: WSJ. More

> FDA warns of potential for poor video quality when using Verathon's recalled video laryngoscopes. Article

Pharma News

@FiercePharma: Elanco debuts immune-boosting cow drug at USDA confab on antibiotic alternatives. More from FierceAnimalHealth | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: First came the recall, then the FDA plant ban, now the warning letter to Emcure plant for faking data. Story | Follow @EricPFierce

@CarlyHFierce: Starting Monday off wrong--watching tons of graphic shingles commercials. | Follow @CarlyHFierce

> Valeant heeds calls for new CEO, links iffy financials to hard-charging 'tone at the top.' Story

> J&J, BMS are delivering solid sales from new meds. The rest of Big Pharma, not so much: Forbes. Report

> NICE does a U-turn on J&J's Zytiga for pre-chemo after drugmaker offers cost-cutting deal. Article

Pharma Marketing News

> Marketers aren't spending enough on ads, researcher says. And yes, that includes pharma. Story

> Pharma's doctor payments do pay off, with more money yielding more scripts: Pro Publica. Article

> Switching study gives Celltrion biosim more ammo in fight for Remicade share. Report

> NICE changes its tune on J&J's Zytiga for pre-chemo prostate cancer treatment. Item

> Note to pharma: Stop fishing social media one hook at a time. A trawler net works much better. More

Animal Health News

> Pet owners boost medication purchases amid record $60B-plus spending: Story

> Five questions for One Health Company founder Ben Lewis. Report

> Elanco debuts immune-boosting cow drug at USDA confab on antibiotic alternatives. Article

> U.K. scientists launch study of emerging tick-borne disease in dogs. Item

> Embark Veterinary launches DNA testing kit for dogs with research applications in mind. More

Biotech IT News

> Following on from GSK deal, WNS adds data analytics capabilities in $17.5M buyout. News

> IMS creates Hootsuite app to help pharma manage social media compliance. Report

> 10x Genomics scoops another $55M to fuel commercialization of long-read tech. Article

> Huawei, WuXi team up to power the China Precision Medicine Initiative. Story

> Zealand, BioSolveIT pool resources to develop peptide design tool. More

Suggested Articles

A new clinical hold is the latest setback for Solid Biosciences and the development of its gene therapy for Duchenne muscular dystrophy.

VBI's Sci-B-Vac protected twice as many people than GSK's Engerix-B did after the second dose.

The notice comes weeks after Amgen revealed it was retreating from its East Coast neuroscience operations.